Cargando…
Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)
The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hy...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993275/ https://www.ncbi.nlm.nih.gov/pubmed/27574399 http://dx.doi.org/10.2147/DDDT.S112873 |
_version_ | 1782449129297805312 |
---|---|
author | Park, Jin-Sun Shin, Joon-Han Hong, Taek-Jong Seo, Hong-Seog Shim, Wan-Joo Baek, Sang-Hong Jeong, Jin-Ok Ahn, Youngkeun Kang, Woong-Chol Kim, Young-Hak Kim, Sang-Hyun Hyon, Min-Su Choi, Dong-Hoon Nam, Chang-Wook Park, Tae-Ho Lee, Sang-Chol Kim, Hyo-Soo |
author_facet | Park, Jin-Sun Shin, Joon-Han Hong, Taek-Jong Seo, Hong-Seog Shim, Wan-Joo Baek, Sang-Hong Jeong, Jin-Ok Ahn, Youngkeun Kang, Woong-Chol Kim, Young-Hak Kim, Sang-Hyun Hyon, Min-Su Choi, Dong-Hoon Nam, Chang-Wook Park, Tae-Ho Lee, Sang-Chol Kim, Hyo-Soo |
author_sort | Park, Jin-Sun |
collection | PubMed |
description | The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, factorial-design study included patients aged ≥20 years with mild to moderate essential hypertension and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. The percentage change from baseline in low-density lipoprotein cholesterol levels was compared between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 162 patients were included. The least square mean percentage change (standard error) from baseline in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the FDC than in the olmesartan medoxomil group (−52.3% [2.8%] vs −0.6% [3.5%], P<0.0001), and the difference was −51.7% (4.1%) (95% confidence interval: −59.8% to −43.6%). The least square mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment was significantly greater in the FDC group than in the rosuvastatin group (−10.4 [1.2] mmHg vs 0.1 [1.6] mmHg, P<0.0001), and the difference was −10.5 (1.8) mmHg (95% confidence interval: −14.1 to −6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This combination may improve medication compliance in patients with a large pill burden. |
format | Online Article Text |
id | pubmed-4993275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49932752016-08-29 Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) Park, Jin-Sun Shin, Joon-Han Hong, Taek-Jong Seo, Hong-Seog Shim, Wan-Joo Baek, Sang-Hong Jeong, Jin-Ok Ahn, Youngkeun Kang, Woong-Chol Kim, Young-Hak Kim, Sang-Hyun Hyon, Min-Su Choi, Dong-Hoon Nam, Chang-Wook Park, Tae-Ho Lee, Sang-Chol Kim, Hyo-Soo Drug Des Devel Ther Original Research The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, factorial-design study included patients aged ≥20 years with mild to moderate essential hypertension and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. The percentage change from baseline in low-density lipoprotein cholesterol levels was compared between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 162 patients were included. The least square mean percentage change (standard error) from baseline in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the FDC than in the olmesartan medoxomil group (−52.3% [2.8%] vs −0.6% [3.5%], P<0.0001), and the difference was −51.7% (4.1%) (95% confidence interval: −59.8% to −43.6%). The least square mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment was significantly greater in the FDC group than in the rosuvastatin group (−10.4 [1.2] mmHg vs 0.1 [1.6] mmHg, P<0.0001), and the difference was −10.5 (1.8) mmHg (95% confidence interval: −14.1 to −6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This combination may improve medication compliance in patients with a large pill burden. Dove Medical Press 2016-08-16 /pmc/articles/PMC4993275/ /pubmed/27574399 http://dx.doi.org/10.2147/DDDT.S112873 Text en © 2016 Park et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Park, Jin-Sun Shin, Joon-Han Hong, Taek-Jong Seo, Hong-Seog Shim, Wan-Joo Baek, Sang-Hong Jeong, Jin-Ok Ahn, Youngkeun Kang, Woong-Chol Kim, Young-Hak Kim, Sang-Hyun Hyon, Min-Su Choi, Dong-Hoon Nam, Chang-Wook Park, Tae-Ho Lee, Sang-Chol Kim, Hyo-Soo Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) |
title | Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) |
title_full | Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) |
title_fullStr | Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) |
title_full_unstemmed | Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) |
title_short | Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) |
title_sort | efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (olsta-d rct: olmesartan rosuvastatin from daewoong) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993275/ https://www.ncbi.nlm.nih.gov/pubmed/27574399 http://dx.doi.org/10.2147/DDDT.S112873 |
work_keys_str_mv | AT parkjinsun efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT shinjoonhan efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT hongtaekjong efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT seohongseog efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT shimwanjoo efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT baeksanghong efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT jeongjinok efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT ahnyoungkeun efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT kangwoongchol efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT kimyounghak efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT kimsanghyun efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT hyonminsu efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT choidonghoon efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT namchangwook efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT parktaeho efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT leesangchol efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong AT kimhyosoo efficacyandsafetyoffixeddosecombinationtherapywitholmesartanmedoxomilandrosuvastatininkoreanpatientswithmildtomoderatehypertensionanddyslipidemiaan8weekmulticenterrandomizeddoubleblindfactorialdesignstudyolstadrctolmesartanrosuvastatinfromdaewoong |